Literature DB >> 17576713

Retinal pigment epithelial tear following intravitreal bevacizumab for choroidal neovascular membrane due to age-related macular degeneration.

Shabeeba R Hannan, Krishnappa C Madhusudhana, Andrew J Lotery, Richard S B Newsom.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17576713      PMCID: PMC1955628          DOI: 10.1136/bjo.2006.101899

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  5 in total

1.  Retinal pigment epithelial tear after transpupillary thermotherapy for choroidal neovascularization.

Authors:  J T Thompson
Journal:  Am J Ophthalmol       Date:  2001-05       Impact factor: 5.258

2.  Retinal pigment epithelial tear following photodynamic therapy for choroidal neovascularization secondary to AMD.

Authors:  M Goldstein; G Heilweil; A Barak; A Loewenstein
Journal:  Eye (Lond)       Date:  2005-12       Impact factor: 3.775

3.  Retinal pigment epithelium tears following verteporfin therapy combined with intravitreal triamcinolone.

Authors:  Stephan Michels; Arne Aue; Christian Simader; Wolfgang Geitzenauer; Stefan Sacu; Ursula Schmidt-Erfurth
Journal:  Am J Ophthalmol       Date:  2006-02       Impact factor: 5.258

4.  Retinal pigment epithelial tear following intravitreal pegaptanib sodium.

Authors:  Mandeep Singh Dhalla; Kevin J Blinder; Asheesh Tewari; Seenu M Hariprasad; Rajendra S Apte
Journal:  Am J Ophthalmol       Date:  2006-04       Impact factor: 5.258

5.  Retinal pigment epithelial rip during krypton red laser photocoagulation.

Authors:  J D Gass
Journal:  Am J Ophthalmol       Date:  1984-12-15       Impact factor: 5.258

  5 in total
  1 in total

Review 1.  Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence?

Authors:  Focke Ziemssen; Salvatore Grisanti; Karl Ulrich Bartz-Schmidt; Martin S Spitzer
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.